Summary
No specific AI-made medical claim (e.g., an indication/dosing instruction/safety claim to verify) was provided for comparison to the label. The message is mostly an extraction/verification narration and does not include a concrete claim that can be checked for support/contradiction.
Category Scores
Accurate Statements
SYMBICORT is an oral inhalation aerosol (pressurized metered-dose inhaler) containing budesonide + formoterol, with strengths 80/4.5 and 160/4.5.
Supported by the provided label excerpts indicating budesonide/formoterol combination and strengths (e.g., Section 1.2 and Section 2 dosing references to SYMBICORT 80/4.5 and 160/4.5).
Key limitations include SYMBICORT is NOT indicated for the relief of acute bronchospasm.
Section 1 (Important Limitations of Use) and reiterated in Sections 5.2/Section 1.1 and 1.2 excerpts.
Unsupported Statements
“Your excerpts clearly state SYMBICORT is an oral inhalation aerosol (pressurized metered-dose inhaler) containing budesonide + formoterol and provide dosing/administration and warnings consistent with that combination.”
This is a general evaluative statement about consistency; it is not a specific, checkable medical claim (and the prompt did not supply the exact AI claim(s) to verify beyond this narrative).
Contradictions
Important Omissions
A specific user/provided claim to evaluate (verbatim statement). Without an exact claim, material omissions from the label regarding that claim cannot be determined.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No actionable patient-safety recommendation or dosing instruction was introduced as an independent AI claim; however, the inability to evaluate a specific claim prevents assurance of on-label alignment for any intended use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Cannot Evaluate
Primary Issue
No exact AI/user medical claim text was provided for claim-by-claim on-label verification; only general narrative statements and label excerpts were included.
Suggested Improvement
Provide the exact single claim (verbatim) you want evaluated (e.g., an indication statement, rescue-use statement, specific dosing regimen, contraindication, or specific interaction claim). Then re-run the audit against the corresponding label sections.